(firstQuint)A Study to Assess the Efficacy and Safety of H.

P.

 Acthar Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis.

 This is a multicenter, multiple dose study to examine the effect of Acthar on functional decline in adult subjects with amyotrophic lateral sclerosis (ALS).

 Approximately 213 subjects will be enrolled.

 Following a screening period of up to 28 days, subjects with ALS and symptom onset (defined as first muscle weakness or dysarthria) 2 years prior to the Screening Visit will be randomized on a 2:1 basis to receive subcutaneous (SC) Acthar 0.

2 mL (16 Units [U]) daily (QD) or SC matching placebo 0.

2 mL QD for 36 weeks, followed by a 3 week taper.

 Subjects who complete the 36 week double-blind treatment period are eligible to enter an Open Label Extension phase where all subjects will receive Acthar 0.

2 mL (16 U) daily.

.

 A Study to Assess the Efficacy and Safety of H.

P.

 Acthar Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis@highlight

This is a multicenter, multiple dose study to examine the effect of H.

P.

 Acthar(R) (Acthar) on functional decline in adult subjects with amyotrophic lateral sclerosis (ALS).

